Search results
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit...
Morningstar· 5 days agoLOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 30, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of Ventyx Biosciences, Inc. (“Ventyx”
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar | JD Supra
JD Supra· 7 days agoOn April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and Johnson’s STELERA® (ustekinumab). The product was approved as a subcutaneous ...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...
Morningstar· 4 days agoFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and reminds investors ...
AbbVie's newer drugs are offsetting losses of the world's once best-selling medication
Quartz· 4 days agoSales of the pharma giant's newer drugs are offsetting its Humira losses.
Op-ed: Here are 6 health-care stocks to watch now, amid a bumpy recovery
CNBC· 6 days agoHealth care, long an ailing stock market sector, has recovered over the past six months, with...
Barrington Research Reaffirms Outperform Rating for Option Care Health (NASDAQ:OPCH)
ETF DAILY NEWS· 2 days agoBarrington Research restated their outperform rating on shares of Option Care Health (NASDAQ:OPCH –...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 5 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
AbbVie (ABBV) to Release Quarterly Earnings on Friday
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, April 26th. Analysts expect the company to announce earnings of ...
William Blair Weighs in on Biogen Inc.’s Q3 2024 Earnings (NASDAQ:BIIB)
ETF DAILY NEWS· 1 day agoBiogen Inc. (NASDAQ:BIIB – Free Report) – Investment analysts at William Blair upped their Q3 2024 earnings per share (EPS) estimates for shares of Biogen in a report issued on Thursday, April ...
Brokerages Set Biogen Inc. (NASDAQ:BIIB) Price Target at $295.58
ETF DAILY NEWS· 4 days agoShares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-seven research firms that are covering the company, Marketbeat reports.